Comment on 3 Key Things Every CAR-T Investor Should Watch

3 Key Things Every CAR-T Investor Should Watch

A long-awaited breakthrough in cancer treatment, chimeric antigen receptor T-cell (CAR-T) therapy, could finally hit the market later this year.First-to-market advantage will likely to go Novartis (NYSE: NVS) with its drug named CTL019. Recently, a panel of FDA advisors unanimously recommended approval for CTL019, which will likely receive a final stamp of approval from the agency by early October.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News